Cipla Q2 FY27 Results: Consolidated Net Profit ₹852 Crore on Total Income of ₹7,555 Crore
Earnings
pharmaceuticals
Blacklitt Research3 min read
Cipla (NSE: CIPLA) reported consolidated total income of ₹7,555.09 crore and net profit of ₹851.51 crore for the quarter ended 30 Sep 2026, it said in a filing on 27 Oct 2026. Standalone total income was ₹5,214.98 crore and standalone net profit was ₹787.03 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
Total income: ₹7,555.09 crore, down 3.9% YoY and up 3.1% QoQ
Net profit: ₹851.51 crore, down 37.1% YoY and up 8.4% QoQ
EPS: ₹10.86 basic, against ₹16.73 a year earlier
Other income: ₹151.16 crore, down 43.8% YoY
Standalone
The company on its own, without its subsidiaries
Total income: ₹5,214.98 crore, down 4.8% YoY and 2.0% QoQ
Net profit: ₹787.03 crore, down 35.0% YoY and 8.7% QoQ
EPS: ₹9.74 basic, against ₹14.99 a year earlier
Dividend: ₹1,050.20 crore paid in the half year ended 30 Sep 2026
Summary
Consolidated ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
7,555.09
7,858.39
-3.9%
7,330.18
+3.1%
Revenue from operations
7,403.93
7,589.44
-2.4%
7,119.28
+4.0%
Other income
151.16
268.95
-43.8%
210.90
-28.3%
851.51
1,353.37
-37.1%
785.55
+8.4%
Profit before tax
1,177.34
1,853.53
-36.5%
1,081.93
+8.8%
Finance costs
16.74
13.18
+27.0%
17.03
-1.7%
Depreciation
344.86
296.99
+16.1%
304.24
+13.4%
Tax expense
320.82
500.46
-35.9%
294.83
+8.8%
Net profit margin
11.27%
17.22%
-5.95 pp
10.72%
+0.55 pp
EPS, basic (₹)
10.86
16.73
-35.1%
9.77
+11.2%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated net profit fell faster than income. Net profit dropped 37.1% YoY while total income fell 3.9%, and profit before tax fell 36.5%. Tax expense of ₹320.82 crore was 27.2% of profit before tax this quarter, against a lower share in the year-earlier quarter.
Other income of ₹151.16 crore is 2.0% of total income, down 43.8% from ₹268.95 crore a year earlier.
Finance costs rose 27.0% to ₹16.74 crore and depreciation rose 16.1% to ₹344.86 crore, but both remain small against total income.
Consolidated net profit is ₹64.48 crore higher than standalone net profit. The company's notes say that from 1 Apr 2026 certain marketing and promotional expenses are shown as a reduction from revenue, with the year-earlier quarter restated, and that this has no impact on profit.
Standalone ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
5,214.98
5,480.38
-4.8%
5,320.43
-2.0%
Revenue from operations
5,067.42
5,225.72
-3.0%
5,077.68
-0.2%
Other income
147.56
254.66
-42.1%
242.75
-39.2%
787.03
1,210.53
-35.0%
862.16
-8.7%
Profit before tax
1,062.43
1,633.34
-35.0%
1,153.62
-7.9%
Finance costs
5.92
2.65
+123.4%
5.68
+4.2%
Depreciation
189.29
141.30
+34.0%
169.39
+11.7%
Tax expense
275.40
422.81
-34.9%
291.46
-5.5%
Net profit margin
15.09%
22.09%
-7.00 pp
16.20%
-1.11 pp
EPS, basic (₹)
9.74
14.99
-35.0%
10.67
-8.7%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit fell 35.0% YoY, in line with profit before tax, which fell 35.0%. Total income fell 4.8%, with other income down 42.1% to ₹147.56 crore and revenue from operations down 3.0%.
Standalone finance costs rose 123.4% to ₹5.92 crore from ₹2.65 crore, and depreciation rose 34.0% to ₹189.29 crore. Tax expense of ₹275.40 crore was 25.9% of profit before tax, and other income was 13.9% of profit before tax.
Against the previous quarter, standalone net profit fell 8.7% while consolidated net profit rose 8.4%. The filing does not state the reason for the fall in standalone other income.
The results include ₹275.91 crore of consolidated and ₹244.37 crore of standalone exceptional losses for the year ended 31 Mar 2026, arising from incremental gratuity and leave liability under the New Labour Codes. The company says these are material and non-recurring. The quarter itself shows no exceptional item.
The results carry an unmodified limited review conclusion from B S R & Co. LLP. The board approved them on 27 Oct 2026.
Inference
The filing shows a standalone dividend of ₹1,050.20 crore paid in the half year ended 30 Sep 2026, but does not give a dividend per share or a record date for the current period.
The filing says the scheme of amalgamation of Inzpera Healthsciences Limited awaits NCLT approval. It also reports NPPA demand notices under litigation of ₹2,011 crore, with the company's legal advice that no provision is necessary. The filing does not say how the outcome of these matters would affect future results, and the amount of any such effect is not known.
Create a free account to read the rest of this article and the analysis that follows.
By continuing you agree to our Terms and Privacy Policy, and to receive updates from Blacklitt by email. You can unsubscribe anytime.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
